Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypercholesterolemia | 5 | 2020 | 75 | 2.220 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2020 | 304 | 1.130 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2020 | 344 | 1.000 |
Why?
|
| Lipoproteins, LDL | 3 | 2016 | 48 | 0.880 |
Why?
|
| Intestinal Mucosa | 6 | 2026 | 254 | 0.840 |
Why?
|
| Stem Cells | 7 | 2026 | 278 | 0.840 |
Why?
|
| Oxidative Stress | 9 | 2018 | 323 | 0.770 |
Why?
|
| Stem Cell Niche | 4 | 2026 | 19 | 0.670 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2016 | 149 | 0.550 |
Why?
|
| Apoptosis | 2 | 2016 | 1100 | 0.540 |
Why?
|
| Mixed Function Oxygenases | 1 | 2017 | 19 | 0.510 |
Why?
|
| Carcinogenesis | 3 | 2025 | 135 | 0.510 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2016 | 10 | 0.470 |
Why?
|
| Intestines | 4 | 2025 | 184 | 0.460 |
Why?
|
| Cell Differentiation | 7 | 2026 | 1391 | 0.450 |
Why?
|
| Colorectal Neoplasms | 2 | 2025 | 290 | 0.440 |
Why?
|
| Intestine, Small | 2 | 2026 | 84 | 0.430 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 198 | 0.430 |
Why?
|
| Aging | 1 | 2020 | 784 | 0.410 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2016 | 216 | 0.390 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1226 | 0.390 |
Why?
|
| Mice | 18 | 2026 | 11185 | 0.390 |
Why?
|
| Ischemia | 6 | 2012 | 203 | 0.380 |
Why?
|
| Cellular Senescence | 1 | 2014 | 121 | 0.380 |
Why?
|
| Disease Models, Animal | 8 | 2026 | 2329 | 0.360 |
Why?
|
| Endothelial Cells | 2 | 2010 | 216 | 0.340 |
Why?
|
| Animals | 22 | 2026 | 21493 | 0.340 |
Why?
|
| MicroRNAs | 2 | 2018 | 714 | 0.340 |
Why?
|
| Mice, Knockout | 5 | 2020 | 2168 | 0.330 |
Why?
|
| Mice, Inbred C57BL | 10 | 2026 | 3506 | 0.320 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 178 | 0.300 |
Why?
|
| Apolipoproteins E | 3 | 2016 | 116 | 0.290 |
Why?
|
| Obesity | 1 | 2017 | 1281 | 0.280 |
Why?
|
| Nitric Oxide Synthase Type III | 5 | 2012 | 28 | 0.280 |
Why?
|
| Regeneration | 2 | 2026 | 127 | 0.270 |
Why?
|
| Signal Transduction | 4 | 2025 | 3170 | 0.260 |
Why?
|
| Myofibroblasts | 1 | 2026 | 22 | 0.240 |
Why?
|
| Cholera | 1 | 2026 | 16 | 0.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2018 | 738 | 0.240 |
Why?
|
| Nitric Oxide | 3 | 2012 | 165 | 0.240 |
Why?
|
| Vibrio cholerae | 1 | 2026 | 18 | 0.240 |
Why?
|
| Phenotype | 3 | 2025 | 1236 | 0.240 |
Why?
|
| Interleukins | 1 | 2026 | 89 | 0.230 |
Why?
|
| Antioxidants | 3 | 2014 | 252 | 0.230 |
Why?
|
| Time Factors | 6 | 2024 | 3779 | 0.230 |
Why?
|
| Cell Plasticity | 1 | 2025 | 24 | 0.220 |
Why?
|
| Intestinal Neoplasms | 1 | 2025 | 15 | 0.220 |
Why?
|
| Polyamines | 1 | 2024 | 13 | 0.210 |
Why?
|
| Adenoma | 1 | 2025 | 70 | 0.210 |
Why?
|
| Fasting | 1 | 2024 | 52 | 0.210 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2025 | 119 | 0.210 |
Why?
|
| Regional Blood Flow | 4 | 2012 | 117 | 0.200 |
Why?
|
| Gastric Mucosa | 1 | 2023 | 53 | 0.200 |
Why?
|
| Hindlimb | 6 | 2013 | 54 | 0.200 |
Why?
|
| Stomach | 1 | 2023 | 87 | 0.200 |
Why?
|
| Colon | 1 | 2024 | 148 | 0.190 |
Why?
|
| Neovascularization, Physiologic | 3 | 2013 | 113 | 0.180 |
Why?
|
| Feeding Behavior | 1 | 2024 | 266 | 0.180 |
Why?
|
| Ascorbic Acid | 2 | 2012 | 53 | 0.180 |
Why?
|
| Arginine | 2 | 2012 | 136 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 408 | 0.170 |
Why?
|
| Methylation | 1 | 2020 | 130 | 0.150 |
Why?
|
| Cell Proliferation | 3 | 2024 | 1044 | 0.150 |
Why?
|
| Muscle, Skeletal | 5 | 2012 | 789 | 0.140 |
Why?
|
| Receptor, Notch1 | 2 | 2018 | 67 | 0.130 |
Why?
|
| Cells, Cultured | 2 | 2014 | 2194 | 0.130 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 30 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 69 | 0.120 |
Why?
|
| Wound Healing | 1 | 2018 | 193 | 0.120 |
Why?
|
| Histones | 1 | 2020 | 497 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 203 | 0.120 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2016 | 5 | 0.120 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2013 | 40 | 0.120 |
Why?
|
| Phosphorylation | 2 | 2016 | 963 | 0.120 |
Why?
|
| Recovery of Function | 4 | 2012 | 293 | 0.120 |
Why?
|
| Goblet Cells | 2 | 2026 | 10 | 0.120 |
Why?
|
| Cell Lineage | 1 | 2017 | 282 | 0.110 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2025 | 10 | 0.110 |
Why?
|
| Bone Morphogenetic Proteins | 2 | 2026 | 65 | 0.110 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 755 | 0.100 |
Why?
|
| Wnt Signaling Pathway | 2 | 2025 | 87 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 859 | 0.100 |
Why?
|
| Telomere Shortening | 1 | 2014 | 9 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2014 | 32 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2014 | 54 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 58 | 0.100 |
Why?
|
| Enzyme Activation | 2 | 2012 | 391 | 0.100 |
Why?
|
| Collateral Circulation | 2 | 2009 | 28 | 0.090 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 42 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 238 | 0.090 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2012 | 206 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 1573 | 0.090 |
Why?
|
| Macrophages | 1 | 2018 | 1042 | 0.090 |
Why?
|
| Peripheral Arterial Disease | 1 | 2013 | 165 | 0.080 |
Why?
|
| Male | 7 | 2025 | 31410 | 0.080 |
Why?
|
| Humans | 6 | 2025 | 65845 | 0.080 |
Why?
|
| Adipocytes | 1 | 2012 | 276 | 0.080 |
Why?
|
| Superoxides | 1 | 2010 | 73 | 0.080 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 83 | 0.080 |
Why?
|
| Adenoviridae | 1 | 2010 | 132 | 0.080 |
Why?
|
| Gene Expression | 2 | 2012 | 856 | 0.070 |
Why?
|
| Mutation | 2 | 2025 | 2675 | 0.070 |
Why?
|
| Chemokine CXCL12 | 1 | 2008 | 27 | 0.070 |
Why?
|
| Blood Flow Velocity | 1 | 2008 | 79 | 0.070 |
Why?
|
| Lower Extremity | 1 | 2010 | 160 | 0.070 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2008 | 67 | 0.070 |
Why?
|
| Transfection | 1 | 2010 | 700 | 0.070 |
Why?
|
| Femoral Artery | 1 | 2008 | 105 | 0.070 |
Why?
|
| Whole-Body Irradiation | 1 | 2026 | 34 | 0.060 |
Why?
|
| Pancreatitis-Associated Proteins | 1 | 2026 | 5 | 0.060 |
Why?
|
| Mucin-2 | 1 | 2026 | 3 | 0.060 |
Why?
|
| Enterocytes | 1 | 2026 | 25 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2012 | 626 | 0.060 |
Why?
|
| Female | 3 | 2025 | 34425 | 0.060 |
Why?
|
| Paneth Cells | 1 | 2025 | 6 | 0.060 |
Why?
|
| Genes, APC | 1 | 2025 | 12 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2009 | 631 | 0.050 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2024 | 55 | 0.050 |
Why?
|
| Pyloric Antrum | 1 | 2023 | 4 | 0.050 |
Why?
|
| Rats | 3 | 2012 | 2005 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2023 | 61 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2024 | 141 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1583 | 0.050 |
Why?
|
| Muscle, Smooth | 1 | 2023 | 135 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2012 | 142 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2024 | 333 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2012 | 371 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2023 | 414 | 0.040 |
Why?
|
| Diet | 1 | 2024 | 540 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2026 | 829 | 0.040 |
Why?
|
| Chromatin | 1 | 2025 | 643 | 0.040 |
Why?
|
| Chemotaxis | 2 | 2009 | 51 | 0.040 |
Why?
|
| Calcium | 2 | 2012 | 587 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2018 | 16 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2018 | 36 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2018 | 48 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2010 | 899 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 2116 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2018 | 321 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2018 | 307 | 0.030 |
Why?
|
| Neoplasms | 1 | 2024 | 1378 | 0.030 |
Why?
|
| Cell Transdifferentiation | 1 | 2013 | 16 | 0.020 |
Why?
|
| NADPH Oxidase 4 | 1 | 2012 | 7 | 0.020 |
Why?
|
| Multipotent Stem Cells | 1 | 2012 | 15 | 0.020 |
Why?
|
| Nitrites | 1 | 2012 | 12 | 0.020 |
Why?
|
| Nitrates | 1 | 2012 | 21 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2012 | 69 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 240 | 0.020 |
Why?
|
| Muscles | 1 | 2012 | 179 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 147 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 484 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 226 | 0.020 |
Why?
|
| Glutathione | 1 | 2010 | 55 | 0.020 |
Why?
|
| Gangrene | 1 | 2009 | 8 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2009 | 15 | 0.020 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2009 | 30 | 0.020 |
Why?
|
| Toes | 1 | 2009 | 14 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 25 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2009 | 43 | 0.020 |
Why?
|
| Tyrosine | 1 | 2009 | 93 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2009 | 301 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 611 | 0.020 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2008 | 7 | 0.020 |
Why?
|
| Insulin | 1 | 2012 | 697 | 0.020 |
Why?
|
| Body Weight | 1 | 2009 | 377 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 234 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 180 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 372 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 514 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 1193 | 0.020 |
Why?
|
| Acute Disease | 1 | 2008 | 665 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 502 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 993 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 745 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 1229 | 0.010 |
Why?
|